Loading market dashboard
AbbVie Inc.
ABBVHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
AbbVie (ABBV) closed at $227.23 in the latest trading session, marking a +1.02% move from the prior day.
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
On CNBC's "Halftime Report Final Trades," Bryn Talkington, managing partner at Requisite Capital Management, named AbbVie (NYSE:ABBV) as her final trade with a price target of $232.
AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.
The market is underestimating these companies' long-term prospects.
The UK cost-effectiveness watchdog on Thursday recommended AbbVie's "guided missile" cancer therapy, Elahere, for patients with a hard-to-treat form of ovarian cancer.
Ten years ago, AbbVie (NYSE:ABBV | ABBV Price Prediction) was a one-drug story.
ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what... This Is What a $1 Million Dividend Portfolio Pays After Taxes
AbbVie's shareholders can sleep easy.
AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.
NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026.
AQUIPTA (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the prophylaxis of
These aren't the most exciting businesses, but they have a lot to offer to long-term investors.
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial Fixed-duration VENCLYXTO-based combination regimens provide patients with additional CLL treatment options that may offer the potential for treatment-free intervals NORTH CHICAGO, Ill., May 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO® (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).
When choosing dividend ETFs, diversification is a top priority.
ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ marks AbbVie's first ADC approved for blood cancer NORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options.
The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid dendritic cell neoplasm, a very rare type of blood cancer.
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
These players are seeing exciting results in clinical trials.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance.
Pfizer's dividend yield is far higher than AbbVie's, but the key issue is whether the payout is safe. AbbVie has been a dividend growth beast for several years, and that trend could very well continue.
Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours.
When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.
Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.
The positive opinion is supported by data from the Phase 3 M20-350 study evaluating the safety and efficacy of MAVIRET ® in adults with acute hepatitis C virus (HCV) infection. MAVIRET is a direct-acting antiviral (DAA) treatment currently approved in the European Union for chronic HCV infection in adults and children aged 3 years and older.
Dividend-growth blue chips like Coca-Cola double income in nine years despite lower starting yields, while high-yield BDCs and REITs with frozen payouts risk delivering less income over a decade than lower-yield growers.
- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline.
Boey ® has received a positive opinion from the CHMP for 30 EU & EEA markets If approved, Boey ® has the potential to be the first and only botulinum neurotoxin serotype E that adult patients can try for the temporary improvement of Glabellar Lines Positive opinion is supported by data from two pivotal Phase 3 trials, which demonstrated rapid results as early as 8 hours and duration of 2-3 weeks 2 NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and global leader in medical aesthetics, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Boey® (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Looking past stocks because they trade at high trailing earnings multiples can be a costly mistake for investors.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Both offer dividends that yield well above the current S&P 500 index average of 1.1%. The first company is already a Dividend King, while the other is very close to joining that celebrated group.
ABBV's neuroscience sales jump 26% in Q1, driven by Vraylar, migraine drugs and Botox as new therapies fuel growth.
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
Realty Income (
AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
On May 12, 2026, AbbVie Inc (ABBV) shares rose 3.1% today, reaching a current price of $207.98. The stock has traded within a 52-week range of $176.57 to $244.8
AbbVie is a compelling 'Buy' as it has strong momentum in existing drugs and has a robust pipeline. Robust Q1 2026 results: net revenue up 12.4% YoY, driven by Immunology (Skyrizi +29%, Rinvoq +20%) and Neuroscience (+24%). Management raised 2026 EPS guidance to $14.18, signaling 42% YoY growth and confidence in ABBV's diversified growth drivers and pipeline.
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
AbbVie remains a buy as fundamentals strengthen and valuation sits near multiyear lows after recent stock underperformance. Q1 net revenues grew 12.4% YoY, indicating robust overall business activity despite some Immunology portfolio shakiness. Raised full-year 2026 EPS guidance signals management confidence, with underlying EPS growth projected at 14% annually after adjusting for IPR&D and milestone impacts.
AbbVie's Skyrizi is one of its most important growth drivers. This drug could face competition from a newer medicine under development that appears more effective.
AbbVie (ABBV) delivered strong Q1 2026 results, with $15B revenue (+12.4% YoY) and Skyrizi sales up 30.9%, prompting raised EPS guidance. Despite analyst concerns over new oral competitors like Icotyde, Skyrizi maintains a clear efficacy advantage and expanding indications, supporting robust growth. ABBV is trading at 14.2x 2026 EPS with a 0.84x PEG, offering compelling value amid 17% projected earnings growth and a $250/share price target.
AbbVie NYSE: ABBV told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.
They have combined for 118 years of consecutive dividend increases.
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026.
AbbVie is a Dividend King that has proven its ability to adapt. Realty Income is the ultimate monthly income play.
By holding these top income stocks in your portfolio, you can have a position in some great companies while also generating cash flow each month.
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
